Work

Insulin degrading enzyme as a therapeutic target for Parkinson’s disease

Year: 2019
Type: dissertation
Abstract: Parkinson’s disease is the second most common neurodegenerative disorder, characterized by motor features that include tremor, bradykinesia and rigidity, possibly resultant from the loss of dopaminergic neurons in the substantia nigra pars compacta. A major pathognomonic feature is the neuronal accumulation of aggregated alpha-synuclein (aSyn), known to trigger neurodegeneration. Recent cohort association studies concluded that type-2 diabetes mellitus (T2DM) increases up to 380% the risk of PD development (young individuals with T2DM). Moreover, T2DM is also associated with faster motor progression and cognitive decline of PD patients. However, the molecular link between this association is not clear. We hypothesize that a possible molecular player underlying both conditions is the insulin degrading enzyme (IDE). IDE presents degradative capacity for different substrates including insulin or amyloid-beta peptide, but not aSyn. Interestingly, in pancreatic cells, IDE interacts with aSyn, preventing its aggregation and toxicity. Moreover, there is an inverse correlation between IDE and aSyn levels in the pancreas. Therefore, we hypothesize that diabetes may induce IDE impairment in the brain, therefore compromising its protective effects against aSyn pathogenicity. In this thesis we aimed to establish a relationship between IDE dysregulation and aSyn pathogenicity, using a two-pronged strategy: analysis of brain samples from animal models of (pre)diabetes; evaluation of IDE-aSyn interplay in a cellular model of Parkinson’s disease. To that purpose, we analyzed protein extracts from brain tissue of WT mice under a control or a high-fat diet (HFD) for 12 weeks (prediabetic model). Remarkably, we showed that diabetes generally decreases the levels of IDE in all analyzed brain areas, at the exception of the hippocampus. In contrast, brain aSyn levels are increased in both hippocampus and cerebellum of these mice. Moreover, an inverse correlation between IDE and aSyn levels was observed (cerebellum). These findings support our hypothesis that diabetes may decrease IDE levels in the brain, and that aSyn levels inversely correlate with IDE levels. To better understand the interplay between IDE-aSyn, we used an established in vitro model of synucleinopathies, based on the overexpression of WT aSyn, or of an aggregation-prone variant of aSyn (SynT) in H4 cells. Notably, both catalytical active IDE-WT or catalytical inactive IDE-E111Q forms of IDE decrease the cytotoxicity of aSyn, but not of SynT. This confirms that IDE is able to reduce aSyn toxicity, and our findings suggest that it occurs in a catalytical-dependent manner. Intriguingly, both IDE-WT and IDE-E111Q increase the intracellular amount of aSyn. Since aSyn toxicity is suppressed, we hypothesize that IDE is diverting aSyn oligomeric/toxic species to more stabilized non-toxic species. In fact, we observed that IDE-E111Q is able to increase the solubility of SynT, and that both IDE-WT and IDE-E111Q favor the formation of larger inclusions of SynT, described to be less toxic. Altogether, we conclude that IDE may play an important role in the brain by suppressing aSyn pathogenesis, and that its potentiation could represent an appealing therapeutic target for Parkinson’s disease. Moreover, a brain-IDEtargeted treatment could also have a great impact in T2DM individuals, to control their high risk to develop PD, particularly of individuals with higher impairment of IDE.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W3002251219
Cites: 223
Cited by:
Related to: 10